TRAVEL . INDUSTRY . SERVICE . EDUCATION . MANAGED CARE

RISK-MITIGATION SERVICES FOR INFECTIOUS DISEASE

Reduce risk for your staff, clients & guests with rapid, fda-authorized testing.

CONTACT US NOW

OUR SOLUTION

  • 100% Confidential
  • Turn-Key Service
  • Global Footprint
  • Enterprise Solutions
  • Scalable Plans
  • HIPAA Compliant

COMPARISON TEST

TEST A OUR TEST TEST C
Serological
RT-qPCR
$
$
$$$
Fastest
Fast
Slow
Hard / Blood
Med / Swab
Easy / Saliva
LEARN MORE

Choose Your Testing Solution

MAIL-IN

Customer receives swab by mail and sends to testing facility. Results are securely and digitally sent within 48 hours of receipt. Useful for dispersed members, longer waiting periods.

Centralized

Customer receives and performs swab at your center. Courier delivers at specific periods to the testing facility with rapid turn around. Great for regular, periodic testing and screening.

On-Site

Testing equipment is installed on-site with FireEye. Rapid on-demand testing that works within your timelines. Best when time is of the essence or convenience is a priority.

  • Travel
  • Industry
  • Managed Care
  • Environmental
  • Services
  • Education

Travel |

Ease Travel Concerns and reduce risk of transmission by screening staff and customer prior to boarding.

  • Members Receive Itinerary Confirmation including Test Kit
  • 96 Hours Prior to Boarding, Members Swab & Mail in Kit
  • Samples are processed
  • e-Data sent to both You and Member 10 Hours Prior to Boarding

Industry |

Reduce Employee Concerns & Down Time: Screen Staff Every 4 Days

  • Staff is swabbed upon entry every 4 days
  • Courier picks up samples
  • Samples are processed
  • You and member receive e-data <24hrs after swab

MGI-Covid19Testing-graphics_HEALTHCARE-12

Managed Care |

Reduce Employee Concerns & Down Time: Screen Staff Every 4 Days

  • Staff is swabbed upon entry every 4 days
  • Courier picks up samples
  • Samples are processed
  • You and member receive e-data <24hrs after swab

Environmental |

Sample High Thoroughfare (e.g. terminals) and Collection Points (e.g. air filters)

  • Numerous locations/devices swabbed
  • Courier delivers samples
  • Samples are processed
  • You and member receive e-data 36hrs after swab

MGI-Covid19Testing-graphics_PROFESSIONAL-13

Services |

High Risk Sites of Circumstances

  • Staff is swabbed and short-term quarantined
  • Sample is immediately processed on-site
  • You and member receive e-data <6 hrs after swab

MGI-Covid19Testing-graphics_EDUCATION-14

Education |

Enrollment and Event

  • Staff is swabbed and short-term quarantined
  • Sample is immediately processed on-site
  • You and member receive e-data <6 hrs after swab

Yes, they have Emergency Use Authorization (EUA.)

Only CLIA* laboratories will do the testing. CLIA laboratories are regulated by the FDA, CMS, and CDC.

(*CLIA – Clinical Laboratory Improvement Amendments.)

CLIA laboratories must comply with HIPPA (Health Assurance Portability and Accountability Act of 1986) regulations for confidentiality.

CLIA labs are regulated to ensure confidentiality throughout the testing process. We do not have access to patient samples or data.

It depends on local and regional regulatory requirements. We adhere to all reporting governmental health and safety requirements.

This assay tests for the presence of SARS-CoV-2 RNA, the genetic building block of the virus. It is more specific and has higher sensitivity than serological testing for antibodies, which screens for a protein you might make DAYS AFTER you have been infected.

Contact us

DOWNLOAD BROCHURE

Real Time Fluorescent RT-PCR kit for detecting 2019 nCoV (SARS-CoV-2) from BGI

This test has been authorized by the FDA under an EUA for use by authorized laboratories;

This test has been authorized only for the detection of nucleic acid from SARs-CoV-2, not for any other viruses or pathogens; and

This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

This test has not been FDA cleared or approved;

For in vitro diagnostic use only.

©2020 MGI